APPENDIX B

CLEAN COPY OF PENDING CLAIMS UPON ENTRY OF INSTANT AMENDMENT

71. A method of stimulating growth of melanocyte precursor cells in a human, the method comprising the step of administering to the human, an amount of a human stem cell factor (SCF) polypeptide and optionally a pharmaceutically acceptable carrier.

72. The method of claim 71 wherein stem cell factor polypeptide selected is selected from the group consisting of amino acids 1-162, 1-164, and 1-165 as set out in SEQ ID NO: 46, said polypeptide optionally consisting of an N-terminal methionine.

73. The method of claim 71 wherein the stem cell factor polypeptide is selected from the group consisting of amino acids 1-100, 1-110, 1-120, 1-123, 1-127, 1-130, 1-133, 1-137, 1-141, 1-145, 1-148, 1-152, 1-156, 1-157, 1-158, 1-159, 1-160, 1-161, 1-163, 1-166, 1-168, 1-173, 1-178, 2-164, 2-165, 5-164, 11-164, 1-180, 1-183, 1-185, 1-188, 1-189, 1-220, and 1-248 as set out in SEQ ID NO: 61, said polypeptide optionally consisting of an N-terminal methionine.

74. The method of claim 71 wherein the stem cell factor polypeptide is selected from the group consisting of amino acids 1-152, 1-157, 1-160, 1-161, and 1-220 as set out in SEQ ID NO: 63, said polypeptide optionally consisting of an N-terminal methionine.

75. A method of treating a pigmentation disorder in a human, the method comprising the step of administering to the human, a therapeutically effective amount of a stem cell factor (SCF) polypeptide and optionally a pharmaceutically acceptable carrier.

76. The method of claim 75 wherein the stem cell factor polypeptide is selected from the group consisting of amino acids 1-162, 1-164, and 1-165 as set out in SEQ ID NO: 46, said polypeptide optionally consisting of an N-terminal methionine.

77. The method of claim 75 wherein the stem cell factor polypeptide is selected from the group consisting of amino acids 1-100, 1-110, 1-120, 1-123, 1-127, 1-130, 1-133, 1-

137, 1-141, 1-145, 1-148, 1-152, 1-156, 1-157, 1-158, 1-159, 1-160, 1-161, 1-163, 1-166, 1-168, 1-173, 1-178, 2-164, 2-165, 5-164, 11-164, 1-180, 1-183, 1-185, 1-188, 1-189, 1-220, and 1-248 as set out in SEQ ID NO: 61, said polypeptide optionally consisting of an N-terminal methionine.

78. The method of claim 75 wherein the stem cell factor polypeptide is selected from the group consisting of amino acids 1-152, 1-157, 1-160, 1-161, and 1-220 as set out in SEQ ID NO: 63, said polypeptide optionally consisting of an N-terminal methionine.

79. The method of claim 71 or 75 wherein the stem cell factor is covalently conjugated to a water soluble polymer.

80. The method of claim 79 wherein the water soluble polymer is polyethylene glycol.

81. The method of claim 71 or 75 wherein the stem cell factor is co administered with at least one other cytokine.

82. The method of claim 79 wherein the stem cell factor is co administered with at least one other cytokine.

83. The method of claim 81 wherein one or more cytokines are selected from a group consisting of Interleukin-1 (IL-1), Interleukin-2 (IL-2), Interleukin-3 (IL-3), Interleukin-4 (IL-4), Interleukin-5 (IL-5), Interleukin-6 (IL-6), Interleukin-7 (IL-7), Interleukin-8 (IL-8), Interleukin-9 (IL-9), Interleukin-10 (IL-10), Interleukin-11 (IL-11), Interleukin-12 (IL-12), erythropoietin (EPO), Granulocyte Colony-stimulating Growth Factor (G-CSF), Macrophage Colony-Stimulating Factor (M-CSF), Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF), Insulin-like Growth Factor-1 (IGF-1), and Leukemic Inhibitory Factor (LIF).

84. The method of claim 82 wherein one or more cytokines are selected from a group consisting of IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, EPO, G-CSF, M-CSF, GM-CSF, IGF-1, and LIF.

85. The method of claim 71 wherein the pharmaceutically acceptable carrier is suitable for topical delivery.

86. The method of claim 71 wherein the pharmaceutically acceptable carrier is suitable for oral delivery.

87. The method of claim 71 wherein the pharmaceutically acceptable carrier is suitable for parenteral delivery.

88. The method of claim 71 wherein the pharmaceutically acceptable carrier is suitable for pulmonary delivery.

89. The method of claim 71 wherein the pharmaceutically acceptable carrier is suitable for nasal delivery.

90. The method of claim 75 wherein the pharmaceutically acceptable carrier is suitable for topical delivery.

91. The method of claim 75 wherein the pharmaceutically acceptable carrier is suitable for oral delivery.

92. The method of claim 75 wherein the pharmaceutically acceptable carrier is suitable for parenteral delivery.

93. The method of claim 75 wherein the pharmaceutically acceptable carrier is suitable for pulmonary delivery.

94. The method of claim 75 wherein the pharmaceutically acceptable carrier is suitable for nasal delivery.

95. The method of claim 75 wherein the pigmentation disorder is melanocytopenia.

96. The method of claim 75 wherein the melanocytopenia is selected from the group consisting of vitilago and piebaldism.